Executive Summary
The USA M&A & Takeover Activity stream reveals a surge in SPAC activity with 8 out of 12 filings tied to blank check companies, including IPOs raising over $1.1B collectively (Averin $284M, Fortress $250M, TRG $200M, Kensington $200M, GalaxyEdge $100M), extensions (Athena), and unit separations (OneIM), signaling robust dealflow targeting tech, AI, quantum, LatAm, automotive/defense/energy. Actual M&A highlights include Pasqal's $2B SPAC merger with Bleichroeder offering $600M proceeds amid 100% 2025 revenue growth, and T Stamp's acquisition of Lexverify for LLM expertise. Camp4 Therapeutics reported mixed FY2025 results with revenue exploding 437% YoY to $3.5M and cash runway to 2028, but net loss widened 55% YoY to $80.4M due to non-cash charges. Period-over-period trends show strong fundraising momentum but pockets of financial strain like Fortress's $13.2M shareholders' deficit post-IPO and Invest's material weaknesses in controls. Portfolio-level patterns indicate heightened M&A appetite in quantum computing, biotech, and AI, with H2 2026 catalysts from closings and trials; implications favor long SPAC proxies and targets ahead of redemptions.
Tracking the trend? Catch up on the prior US Merger & Acquisition SEC Filings digest from March 04, 2026.
Investment Signals(10)
- β²
Definitive $2B pre-money SPAC merger with 100% 2025 revenue growth (unaudited), $600M gross proceeds including $200M convertible notes, 7 deployed quantum computers, and ramp to 13 QPUs/year
- Camp4 Therapeuticsβ(BULLISH)β²
FY2025 revenue +437% YoY to $3.5M, cash +71% to $109.5M extending runway to 2028 via $17.5M GSK + $50M placement + $30M offering, R&D expenses flat -1.5% YoY
- Averin Capital Acquisition Corp.β(BULLISH)β²
IPO over-allotment partial exercise adds 3.4M units/$33.86M, total proceeds $284M in trust vs original $252M, underwriters retain 364k unit option
- T Stamp Inc.β(BULLISH)β²
Completed 100% acquisition of Lexverify (UK LLM expert) via stock (25% upfront, 75% deferred over 270 days), adds UK access and non-compete protections, accelerates on change of control
- β²
$200M IPO + $2.25M private placement fully in trust, targeting LatAm combos post-Nov 2025 incorporation
- β²
$200M IPO priced at $10/unit (20M units) targeting automotive/defense/energy/AI, listing March 4 2026 with 45-day 3M over-allotment
- GalaxyEdge Acquisition Corpβ(BULLISH)β²
$100M IPO (10M units) priced, NYSE listing March 4 2026, 1.5M over-allotment option, targeting NA/SA/EU/Asia
- β²
$498 trust deposit extends initial business combo deadline to April 14 2026 (7th of 9 months), no other financial impacts
- Fortress Value Acquisition Corp. Vβ(MIXED BULLISH)β²
$250M IPO + $2M private placement in trust despite $13.2M shareholders' deficit from liabilities, 45-day 3.75M over-allotment
- OneIM Acquisition Corp.β(NEUTRAL BULLISH)β²
Units separate trading from March 6 2026 (OIMAU to OIM + OIMAW), each 1 share + 1/6 warrant at $11.50 exercise
Risk Flags(7)
- Camp4 Therapeutics/Net Lossβ[HIGH RISK]βΌ
FY2025 net loss widened 55% YoY to $80.4M from $51.8M driven by $29.8M non-cash derivative loss, G&A +17% to $17.4M, paused CMP-001 investment
- Invest Acquisition Corporation/Auditor Change[MEDIUM RISK]βΌ
Dismissed Marcum LLP Jan 14 2026 due to acquisition by CBIZ, prior material weaknesses in accrued expenses/trust interest, FY2023 going concern paragraph, 10-K for 2024 still unfiled
- βΌ
Post-$250M IPO, $14.8M liabilities and $13.2M shareholders' deficit from accumulated deficit despite $251.6M assets
- Relativity Acquisition Corp/Proxy Controlβ[MEDIUM RISK]βΌ
Initial stockholders hold 98.5% of 4.3M shares, approve merger/Redemption Limit/Adjournment without public support, $6.56M at risk but differing director interests
- βΌ
H2 2026 close subject to shareholder redemptions, regulatory approvals, 3 more QPUs in production but unproven ramp
- T Stamp Inc./Deferred Paymentsβ[LOW-MEDIUM RISK]βΌ
Lexverify acquisition 75% deferred over 270 days subject to withholdings for warranties/set-offs, no dollar price disclosed
- Camp4 Therapeutics/R&D Pivotβ[MEDIUM RISK]βΌ
Paused CMP-001 to explore partnerships, ongoing GLP tox for CMP-002 with Ph1/2 trial 2H 2026 only preclinical data so far
Opportunities(7)
- Bleichroeder/Pasqal Mergerβ(OPPORTUNITY)β
$2B quantum valuation with 25 clients (IBM/NVIDIA), $80M booked business, $600M proceeds for 13 QPUs/year ramp, close H2 2026 vs peers like IonQ
- Camp4 Therapeutics/Pipelineβ(OPPORTUNITY)β
$109.5M cash to 2028 funds CMP-002 Ph1/2 2H 2026 (SYNGAP1 protein boost in NHPs), GSK $17.5M upfront validates RNA tech post-CMP-001 pause
- T Stamp/Lexverify Acquisitionβ(OPPORTUNITY)β
Stock-for-stock adds LLM training/UK access, 12-mo non-competes, employee retention commitments, accelerates on T Stamp M&A
- SPAC IPO Wave (Averin/Fortress/TRG/Kensington/GalaxyEdge)(OPPORTUNITY)β
$1.1B+ raised in 1 week at $10/unit, over-allotments signal demand, targets AI/quantum/LatAm/auto/defense for de-SPAC upside
- Athena Extension(OPPORTUNITY)β
7th/9th monthly trust deposit to April 14 2026 buys time for combo amid SPAC extension trend
- Relativity Merger Proxy(OPPORTUNITY)β
DEFM14A vote with 98.5% insider control ensures approval, $6.56M skin-in-game, monitor redemptions pre-close
- Kensington Sector Focus(OPPORTUNITY)β
$200M for automotive/defense/energy/AI targets, units with split warrants (1/4 Class1 + 3/4 Class2) for asymmetric upside
Sector Themes(6)
- SPAC Fundraising Boomβ
8/12 filings (67%) from blank checks raising $1.1B+ (Averin $284M to Galaxy $100M) in March 2026, all at $10/unit with over-allotments, implies hot M&A market for tech/AI/LatAm/defense vs 2025 slowdown [BULLISH IMPLICATION: Pre-deal liquidity plays]
- Extension & Maintenance Activityβ
Athena's 7th extension to April + OneIM unit split signals SPAC managers extending runway amid deal hunt, 2/12 filings but common in maturing SPACs [NEUTRAL: Watch redemptions]
- Quantum/AI M&A Momentumβ
Pasqal $2B SPAC (100% rev growth, NVIDIA/IBM clients) + T Stamp Lexverify LLM buyout highlight tuck-in deals, advisors Lazard/Cantor add credibility [BULLISH: Sector rotation into compute]
- Biotech Mixed Earningsβ
Camp4 sole FY2025 reporter with rev +437% YoY but loss +55%, cash +71% to 2028 via deals/placements, pause in one program for partnerships [MIXED: Pipeline catalysts outweigh losses]
- Post-IPO Balance Sheet Strainβ
Fortress $13.2M deficit despite $250M trust, over-allotment liabilities common, contrasts pure cash raises [BEARISH: Sponsor dilution risk]
- Auditor/Control Weaknessesβ
Invest's Marcum dismissal + material weaknesses/going concern echo SPAC governance issues, 10-K delay flags filing risks [CAUTION: Due diligence essential]
Watch List(8)
H2 2026 merger close, monitor shareholder redemptions/regulatory approvals post-filing [H2 2026]
CMP-002 GLP tox completion + Ph1/2 initiation, partnership talks for CMP-001 [2H 2026]
2 more potential extensions to June 2026, business combo announcement [April 14 2026]
Remaining 364k over-allotment exercise within 45 days [~April 19 2026]
- Relativity Acquisitionβ(IMMINENT)π
Special meeting proxy vote on merger/Redemption Limit (revocation by Dec 5 2025, but ongoing)
- Fortress Value Acquisition Vπ
Over-allotment 3.75M shares decision [~April 13 2026]
- Kensington Capital VIπ
IPO closing + unit trading start [March 5 2026]
- Invest Acquisitionπ
2024 10-K filing + CBIZ audit progress amid prior weaknesses [Q1 2026]
Filing Analyses(12)
05-03-2026
Pasqal Holding SAS, a neutral atom quantum computing company co-founded by Nobel Prize Laureate Alain Aspect, announced a definitive business combination with Bleichroeder Acquisition Corp. II (BBCQ), valuing Pasqal at $2B pre-money and providing over $600M in gross proceeds including $200M convertible financing. The deal highlights Pasqal's 7 deployed quantum computers, over 25 clients like IBM and NVIDIA, approximately 100% revenue growth in 2025 (unaudited), and $80M in booked business. The transaction is expected to close in H2 2026, subject to approvals, with risks including shareholder redemptions and regulatory hurdles.
- Β·Pasqal has 3 additional quantum computers in production.
- Β·Ability to ramp up to 13 QPUs per annum across facilities in France and Canada.
- Β·Advisors: Lazard Freres SAS (Pasqal), Cantor Fitzgerald & Co. (Bleichroeder).
05-03-2026
Invest Acquisition Corporation (formerly Investcorp Europe Acquisition Corp I) dismissed Marcum LLP as its independent registered public accounting firm on January 14, 2026, due to CBIZ CPAs P.C. acquiring Marcum's attest business effective November 1, 2024, and immediately engaged CBIZ CPAs, with approval from the Audit Committee. There were no disagreements or reportable events with Marcum except for previously disclosed material weaknesses in internal controls over accrued expenses and trust account interest, and Marcum's FY 2023 audit report included a going concern explanatory paragraph. No consultations occurred with CBIZ prior to engagement.
- Β·Marcum continued serving as auditor through January 14, 2026.
- Β·Company's Annual Report on Form 10-K for year ended December 31, 2024, has not yet been filed with the SEC.
- Β·Marcum provided a concurring letter dated March 4, 2026, attached as Exhibit 16.1.
05-03-2026
OneIM Acquisition Corp., a blank check company, announced on March 5, 2026, that commencing March 6, 2026, holders of its units (OIMAU) may elect to separately trade Class A Ordinary Shares (OIM) and Warrants (OIMAW) on the Nasdaq Global Market. Each unit consists of one Class A ordinary share, par value $0.0001, and one-sixth of one redeemable warrant exercisable for one share at $11.50. Units not separated will continue trading under OIMAU, with no fractional warrants issued upon separation.
- Β·Transfer agent: Continental Stock Transfer & Trust Company
- Β·Company address: 11th Floor, 390 Park Avenue, New York, NY 10022
- Β·Phone: (646) 222-9570
- Β·EIN: 98-1883783
- Β·Cayman Islands incorporation
05-03-2026
CAMP4 reported full year 2025 financial results with cash and equivalents rising 71% to $109.5M from $64.0M, extending runway into 2028, driven by $17.5M GSK upfront, $50M private placement upfront, and $30M stock offering; revenue surged 437% YoY to $3.5M. However, net loss widened 55% to $80.4M from $51.8M primarily due to a $29.8M non-cash derivative liability loss, R&D expenses were nearly flat down 1.5% to $38.2M, G&A rose 17% to $17.4M, and the company paused further investment in CMP-001.
- Β·GLP toxicology studies ongoing for CMP-002, with global Phase 1/2 clinical trial initiation expected as early as 2H 2026
- Β·Preclinical data showed CMP-002 increased SYNGAP1 protein levels and rescued behavioral phenotypes in mice and NHPs
- Β·Strategic decision to pause CMP-001 development and explore partnerships
- Β·Working capital $98.6M as of Dec 31, 2025 vs $56.8M prior year
- Β·Accumulated deficit $292.2M as of Dec 31, 2025
05-03-2026
Athena Technology Acquisition Corp. II deposited $497.74 into its trust account on March 4, 2026, to extend the deadline for consummating its initial business combination by one month, from March 14, 2026, to April 14, 2026. This represents the seventh of up to nine potential monthly extensions permitted under the company's Amended and Restated Certificate of Incorporation. No other material financial impacts or performance metrics were reported.
- Β·Company is an emerging growth company.
- Β·Fiscal year end: December 31.
- Β·SEC file number: 001-41144.
05-03-2026
Averin Capital Acquisition Corp., a blank check company, announced the partial exercise of its IPO over-allotment option on March 5, 2026, with underwriters purchasing 3,386,008 additional units at $10.00 each, generating $33.86M in gross proceeds. This brings total public offering units to 28,386,008 and total gross proceeds (including original IPO of 25M units for $250M and private placement of 200k units for $2M) to $283.86M, all placed in a trust account. No negative performance metrics were reported.
- Β·Underwriters retain 45-day over-allotment option to purchase up to 363,992 additional units.
- Β·Private Placement Units are not redeemable and exercisable on cashless basis, identical to IPO units except as disclosed in S-1 (File No. 333-293082).
- Β·IPO registration statement effective February 18, 2026.
05-03-2026
T Stamp Inc. completed the acquisition of 100% of Lexverify Ltd., a UK-based private company, on February 27, 2026, through a share purchase agreement payable entirely in Class A Common Stock structured as 25% upfront (Completion Consideration) and 75% deferred in three equal tranches over 90, 180, and 270 days. The deal, described as limited in size, aims to add expertise in training and using large language models while providing UK market access. No specific purchase price dollar amount was disclosed, and deferred payments are subject to potential withholdings for warranties or set-offs.
- Β·Certain Lexverify sellers agreed to 12-month non-compete and non-solicit restrictions post-Closing.
- Β·Company committed to approving continuing employment of Lexverify employees on substantially similar compensation, benefits, and equity terms.
- Β·Deferred Consideration accelerates upon change of control of T Stamp Inc.
05-03-2026
Fortress Value Acquisition Corp. V consummated its IPO on February 27, 2026, issuing 25,000,000 Class A ordinary shares at $10.00 per share for gross proceeds of $250M, alongside a private placement of 200,000 shares to sponsor Fortress Value Acquisition Sponsor V LLC for $2M, with $250M placed in trust. The balance sheet as of that date reflects total assets of $251.6M, including $250M in trust and $1.6M cash outside trust. However, it shows total liabilities of $14.8M and a shareholders' deficit of $13.2M driven by accumulated deficit.
- Β·Underwriter granted 45-day option to purchase up to 3,750,000 additional Class A ordinary shares for over-allotments.
- Β·Over-allotment option liability of $359,250 recorded.
- Β·7,187,500 Class B ordinary shares issued, including 937,500 subject to forfeiture if over-allotment not exercised.
- Β·IPO registration statement effective February 25, 2026.
05-03-2026
TRG Latin America Acquisitions Corp., a blank check company, consummated its initial public offering (IPO) on February 27, 2026, selling 20,000,000 units at $10.00 per unit, generating gross proceeds of $200 million. Simultaneously, the company completed a private placement of 225,000 units to its sponsor, TRG Latin America Acquisitions LLC, for $2.25 million. A total of $200 million from the IPO and private placement net proceeds was deposited into a trust account.
- Β·Company incorporated November 7, 2025, as Cayman Islands exempted company targeting business combination in Latin America.
- Β·IPO registration statement effective February 25, 2026.
- Β·Transaction costs totaled $6,768,470, including $250,000 cash underwriting fee.
- Β·5,750,000 Class B ordinary shares issued and outstanding, with up to 750,000 subject to forfeiture if over-allotment option not exercised.
- Β·Trust account invested in U.S. government treasury obligations or money market funds.
05-03-2026
Relativity Acquisition Corp, a SPAC, has filed a DEFM14A proxy statement for a special stockholder meeting to approve a business combination merger forming Pubco, along with a Redemption Limitation Amendment and Adjournment Proposal. Initial Stockholders control 98.5% of the 4,309,988 outstanding Common Shares, ensuring quorum and ability to approve all proposals without public stockholder support. Directors and officers have differing interests, including $6.56M at risk from Founder Shares and Private Placement Units.
- Β·Proxy revocation deadline: 5:00 p.m. Eastern time on December 5, 2025
- Β·IPO closing date: February 15, 2022
- Β·Company address: 3753 Howard Hughes Pkwy, Suite 200, Las Vegas, Nevada 89169
05-03-2026
Kensington Capital Acquisition Corp. VI, a blank check company targeting mergers in automotive, defense, energy, and AI sectors, announced the pricing of its $200M initial public offering of 20,000,000 units at $10.00 per unit on March 3, 2026, with expected closing on March 5, 2026. Units, consisting of one Class A ordinary share, one-quarter Class 1 redeemable warrant, and three-quarters Class 2 redeemable warrant, are set to list on NYSE under 'KCAC.U' starting March 4, 2026. Underwriters Cohen & Company Capital Markets and Drexel Hamilton have a 45-day option for up to 3,000,000 additional units.
- Β·Registration statement effective March 3, 2026.
- Β·Class 1 warrants and new units approved for listing under 'KCAC.W' and 'KCA.U' upon separate trading.
05-03-2026
GalaxyEdge Acquisition Corp, a Cayman Islands blank check company, priced its initial public offering of 10,000,000 units at $10.00 per unit, raising $100M, with units expected to begin trading on NYSE under 'GLEDU' on March 4, 2026, and closing on March 5, 2026. The offering includes a 45-day over-allotment option for up to 1,500,000 additional units. Polaris Advisory Partners serves as sole book-running manager, with no reported declines or flat metrics in this IPO announcement.
- Β·S-1 registration statement (File No. 333-290899) declared effective February 26, 2026; Post-Effective Amendments filed March 2 and 3, 2026.
- Β·Target focus: business combinations in North America, South America, Europe, or Asia.
- Β·Contact: (212) 574-4425
Get daily alerts with 10 investment signals, 7 risk alerts, 7 opportunities and full AI analysis of all 12 filings
πΊπΈ More from United States
View all βMarch 26, 2026
US Pre-Market SEC Filings Roundup β March 26, 2026
US Pre-Market SEC Filings Roundup
March 25, 2026
US Pre-Market SEC Filings Roundup β March 25, 2026
US Pre-Market SEC Filings Roundup
March 25, 2026
Biotech Small-Cap Approvals β March 25, 2026
Biotech Small-Cap Approvals
March 25, 2026
New Drug Approvals (Original) β March 25, 2026
New Drug Approvals (Original)